AnaptysBio
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 months.
- Its last 3 Sell calls were followed by a 17% average decline over the next quarter.
- Recent price momentum is +34.0% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 16.9% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation B-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 9.0x | Better than 85% |
| Forward P/E | 9.5x | Better than 83% |
| Price / Sales | 5.9x | Better than 18% |
| P/E vs own 5-yr range | 93rd pctl | Better than 11% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability B-
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | 20.4% | Better than 77% |
| Net margin | -5.6% | Better than 19% |
| Return on equity | -24.5% | Better than 15% |
| Return on invested capital | 52.4% | Better than 99% |
Momentum C+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -19.2% | Better than 32% |
| 6-month return | -21.9% | Better than 25% |
| 12-month return (ex latest month) | 84.5% | Better than 93% |
| Distance below 52-week high | 35.6% | Better than 34% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 9.1x | Better than 93% |
| Debt to assets | 3.9% | Better than 82% |
| Interest coverage | 0.8x | Better than 28% |
| Free cash flow / net income | 409.3% | Better than 91% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 71.6% | Better than 76% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 47.40
- Open
- 47.49
- Day range
- 46.05 - 47.71
- Avg price
- 46.72
- Volume
- 432.45K
- Turnover
- 20.21M
- Turnover ratei
- 2.13%
- Volume ratioi
- 0.81
- Amplitudei
- 3.50%
- 52-week rangei
- 26.01 - 72.36
Valuation
- P/Ei
- 8.33
- P/E (TTM)i
- 8.98
- P/Bi
- 66.61
- EPSi
- 5.60
- Book value / shi
- 0.70
- Net profit
- 166.49M
- Net assets
- 20.81M
Share structure
- Market cap
- 1.39B
- Float capi
- 948.03M
- Shares out
- 29.73M
- Float sharesi
- 20.33M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2017-01-26
35.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-612.54K net over the window
Short interest
- Shares short
- 5.05M
- % of floati
- 16.89%
- Days to coveri
- 10.79
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of AnaptysBio (ANAB)?
AnaptysBio last traded at 46.63. This page shows a periodic quote snapshot. Check the displayed quote time.
What is AnaptysBio's market cap?
About 1.39B.
What is the P/E ratio of AnaptysBio?
The trailing twelve-month P/E is 8.98. The Valuation tab shows it against the stock's own five-year range.
Does AnaptysBio pay a dividend?
AnaptysBio does not currently pay a regular dividend.
Is AnaptysBio a buy according to analysts?
The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 80.00, which implies 71.6% upside from the current price. This is not investment advice.
What is AnaptysBio's StockVane Quant Rating?
The StockVane Momentum strategy currently rates AnaptysBio a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
AnaptysBio discussion 0 comments